Pathophysiology of Dyslipidemia and its Management by PCSK9 Inhibitors: A Literature Review

Tooba Adnan, Munazza Ahmad, Wardah M Chaudhri, Ahsan Zil-E-Ali, Muhammad Umar Masood Gondal, Syed Muhammad Hammad Ali, Maira Nusrat, Saad Wasiq

Abstract

Dyslipidemia is a disease of abnormal lipid levels in the blood that contributes to the atherosclerotic process. This atherogenic process leads to the formation of plaque and also leads to thromboembolic events and other vascular accidents. It is known that high-density lipoprotein cholesterol serves as a protective effect on the vessel wall and causes the reduction in the progression of atherosclerosis. And multiple interventions are directed in maintaining a higher level of the aforementioned lipoprotein cholesterol. While the low-density lipoprotein stays controversial but lowering its levels through various therapeutic agents is the main goal in the management of dyslipidemia. A newer group of drugs, PCSK9 inhibitors lowers the levels of low-density lipoprotein through modulating PCKS9 gene involved in cholesterol metabolism and affects the levels of the lipoproteins by controlling the receptors. The inhibitors of this gene decrease PCSK9-induced low-density lipoprotein receptor degradation in the lysosomes of hepatocytes increasing its recycling and expression on the cell surface, causing increased clearance of low-density lipoprotein from the circulation. These drugs Alicuromab, Evolocumab and along with other agents can be a novel approach in controlling dyslipidemic state. This review revisits the literature in understanding the pathophysiology of dyslipidemia along with its management by PCKS9 inhibitors, its mechanism of action, its pharmacokinetics, the results of the clinical trials and the limitations in its application.

Keywords

PCSK9 Gene, PCSK9 Inhibitors, Hyperlipidemia, Cardiovascular Diseases

Full Text:

PDF

References

Ross R, Harker L.: Hyperlipidemia and atherosclerosis. Science. 1976, 4258:1094-100. 10.1126/science.822515

Toth PP: The “good cholesterol”. Circulation. 2005, 5:89-91. 10.1161/01.CIR.0000154555.07002.CA

Cilla M, Pena E, Martinez MA: Mathematical modelling of atheroma plaque formation and development in coronary arteries. Journal of the Royal Society, Interface. 2014, 90:20130866. 10.1098/rsif.2013.0866

Al-Rasadi K, Al-Waili K, Al-Sabti HA, et al: Criteria for diagnosis of familial hypercholesterolemia: A comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population. Oman medical journal. 2014, 2:85.

Stefanick ML, Mackey S, Sheehan M, et al: Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998, 339:12-20. 10.1056/NEJM199807023390103

Kannel WB, Dawber TR, Friedman GD, et al: Risk factors in coronary heart disease: an evaluation of several serum lipids as predictors of coronary heart disease: The Framingham Study. Annals of internal medicine. 1964, 5:888-99. 10.7326/0003-4819-61-5-888

Rader DJ, Hovingh GK.: HDL and cardiovascular disease. The Lancet. 2014, 9943:618-25. 10.1016/S0140-6736(14)61217-4

Toth PP, Barter PJ, Rosenson RS, et al: High-density lipoproteins: a consensus statement from the National Lipid Association. Journal of clinical lipidology. 2013, 5:484-525. 10.1016/j.jacl.2013.08.001

Goff DC, Lloyd-Jones DM, Bennett G, et al: 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014, 25:49-73. 10.1161/01.cir.0000437741.48606.98

Olsson AG, Schwartz GG, Szarek M, et al: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. European heart journal. 2005, 9:890-6. 10.1093/eurheartj/ehi186

Ray KK, Cannon CP, Cairns R, et al: Prognostic utility of ApoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromesArterioscler., Thromb., Vasc. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009, 3:424-30. 10.1161/ATVBAHA.108.181735

Rader DJ, deGoma EM.: Approach to the patient with extremely low HDL-cholesterol. J. Clin. Endocrinol. Metab. 2012, 10:3399-407. 10.1210/jc.2012-2185

Ridker PM.: LDL cholesterol controversies and future therapeutic directions. The Lancet. 2014, 9943:607-17. 10.1016/S0140-6736(14)61009-6

Ahn CH, Choi SH: New drugs for treating dyslipidemia: beyond statins. Diabetes Metab. 2015, 2:87-94. 10.4093/dmj.2015.39.2.87

Horton JD, Cohen JC, Hobbs HH: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007, 2:71-7. 10.1016/j.tibs.2006.12.008

Choi SH, Ginsberg HN: Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol. Metab. 2011, 9:353-63. 10.1016/j.tem.2011.04.007

Cuchel M, Bloedon LT, Szapary PO, et al: Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 2007, 2:148-56. 10.1056/NEJMoa061189

Sahebkar A, Watts GF: New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?. Cardiovasc Drug Ther. 2013, 27:559-567.

Seidah NG, Benjannet S, Wickham L, et al: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC- 1): liver regeneration and neuronal differentiation. Proc.Natl. Acad .Sci U S A. 2003, 3:928-933. 10.1073/pnas.0335507100

Maxwell KN, Soccio RE, Duncan EM, et al: Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 2003, 11:2109-19. 10.1194/jlr.M300203-JLR200

Basak A: Inhibitors of proprotein convertases. J. Mol. Med. 2005, 83:844-55. 10.1007/s00109-005-0710-0

Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA: Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proc .Natl. Acad. Sci U S A. 2007, 104:14604-9. 10.1073/pnas.0703402104

Benjannet S, Rhainds D, Essalmani R, et al: NARC-1/PCSK9 and its natural mutants zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 2004, 279:48865-75. 10.1074/jbc.M409699200

Brown M, Goldstein J.: Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest. 1983, 72:743. 10.1172/JCI111044

Goldstein L, Brown S: The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977, 46:897930. 10.1146/annurev.bi.46.070177.004341

Cohen JC, Boerwinkle E, Mosley Jr TH, et al: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006, 354:1264-72. 10.1056/NEJMoa054013

Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006, 79:514-23. 10.1086/507488

Zhang D-W, Lagace TA, Garuti R et al: Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007, 282:18602-12. 10.1074/jbc.M702027200

Fisher TS, Surdo PL, Pandit S, et al: Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 2007, 282:20502-12. 10.1074/jbc.M701634200

Rudenko G, Henry L, Henderson K, et al.: Structure of the LDL receptor extracellular domain at endosomal pH. Science. 2002, 298:2353-2358. 10.1126/science.1078124

Kwon HJ, Lagace TA, Mcnutt MC, Horton JD, Deisenhofer J: Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA. 2008, 105:1820-1825. 10.1073/pnas.0712064105

Maxwell KN, Fisher EA, Breslow JL: Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005, 102:2069-2074. 10.1073/pnas.0409736102

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol. (2015). Accessed: May 21, 2018: https://www.news-medical.net/news/20150725/FDA-approves-Praluent-(alirocumab)-Injection-for-treatment-of-patients-with-high-LDL-cholesterol.aspx.

Noto D, Cefalù AB, Averna MR: Beyond statins: new lipid lowering strategies to reduce cardiovascular risk. Curr Atheroscler Rep. 2014, 16:414. 10.1007/s11883-014-0414-4

Raal FJ, Stein EA, Dufour R, Turner T, et al.: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD- 2): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015, 385:331-340. 10.1016/S0140-6736(14)61399-4

Koren MJ, Giugliano RP, Raal FJ, et al.: Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014, 129:234-243. 10.1161/CIRCULATIONAHA.113.007012

Dadu RT, Ballantyne CM: Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014, 11:563-575. 10.1038/nrcardio.2014.84

Everett BM, Smith RJ, Hiatt WR: Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs. N Engl J Med. 2015, 373:1588-1591. 10.1056/NEJMp1508120

Poirier S, Prat A, Marcinkiewicz E, et al.: Implication of the proprotein convertase NARC‐1/PCSK9 in the development of the nervous system. J Neurochem. 2006, 98:838-850. 10.1111/j.1471-4159.2006.03928.x

Rashid S, Curtis DE, Garuti R, et al.: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005, 102:5374-5379. 10.1073/pnas.0501652102

Cohen J, Pertsemlidis A, Kotowski IK, et al.: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature genetics. 2005, 37:161-165. 10.1038/ng1509

Reyes-soffer G, Pavlyha M, Ngai C, et al.: Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. 2017, 135:352-362. 10.1161/CIRCULATIONAHA.116.025253

Latimer J, Batty JA, Neely RDG, et al.: PCSK9 inhibitors in the prevention of cardiovascular disease. J Throm Thrombolysis. 2016, 42:405-419. 10.1007/s11239-016-1364-1

McDonagh M, Peterson K, Holzhammer B, et al.: A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm. 2016, 22:641-653. 10.18553/jmcp.2016.22.6.641

Nicholls SJ, Puri R, Anderson T, et al.: Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016, 316:2373-2384. 10.1001/jama.2016.16951

Chaudhary R, Garg J, Shah N, Sumner A: PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol. 2017, 9:76-91. 10.4330/wjc.v9.i2.76

Minder CM, Blumenthal RS, Blaha MJ: Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol. 2013, 28:554-560. 10.1097/HCO.0b013e32836429e6

Group HPSC: MRC/BHF heart protection study: randomised placebo-controlled trial of cholesterol-lowering with simvastatin in 20,536 high-risk individuals. Lancet. 2002, 360:7-22. 10.1016/S0140-6736(02)09327-3

Anderson JL, Heidenreich PA, Barnett PG, et al.: ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures. Circulation. 2014, 129:2329 45. 10.1016/j.jacc.2014.03.016

Dias CS, Shaywitz AJ, Wasserman SM, et al.: Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012, 60:1888-98. 10.1016/j.jacc.2012.08.986

Refbacks

  • There are currently no refbacks.